Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
Ajouter des filtres








Gamme d'année
1.
Biol. Res ; 47: 1-7, 2014. ilus, graf, tab
Article Dans Anglais | LILACS | ID: biblio-950768

Résumé

BACKGROUND: Acetylcholine (ACh) is known to be a key neurotransmitter in the central and peripheral nervous systems, which is also produced in a variety of non-neuronal tissues and cell. The existence of ACh in maxilla in vivo and potential regulation role for osteogenesis need further study. RESULTS: Components of the cholinergic system (ACh, esterase, choline acetyltransferase, high-affinity choline uptake, n- and mAChRs) were determined in maxilla of rat in vivo, by means of Real-Time PCR and immunohistochemistry. Results showed RNA for CarAT, carnitine/acylcarnitine translocase member 20 (Slc25a20), VAChT, OCTN2, OCT1, OCT3, organic cation transporter member 4 (Slc22a4), AChE, BChE, nAChR subunits α1, α2, α3, α5, α7, α10, ß1, ß2, ß4, γ and mAChR subunits M1, M2, M3, M4, M5 were detected in rat's maxilla. RNA of VAChT, AChE, nAChR subunits α2, ß1, ß4 and mAChR subunits M4 had abundant expression (2(-ΔCt) > 0.03). Immunohistochemical staining was conducted for ACh, VAChT, nAChRα7 and AChE. ACh was expressed in mesenchymal cells, chondroblast, bone and cartilage matrix and bone marrow cells, The VAChT expression was very extensively while ACh receptor α7 was strongly expressed in newly formed bone matrix of endochondral and bone marrow ossification, AchE was found only in mesenchymal stem cells, cartilage and bone marrow cells. CONCLUSIONS: ACh might exert its effect on the endochondral and bone marrow ossification, and bone matrix mineralization in maxilla.


Sujets)
Animaux , Mâle , Rats , Moelle osseuse/physiologie , Acétylcholine/métabolisme , Cartilage/physiologie , Agents cholinergiques/métabolisme , Maxillaire/métabolisme , Ostéogenèse/physiologie , Trame osseuse/métabolisme , Calcification physiologique/physiologie , Cellules de la moelle osseuse/métabolisme , Immunohistochimie , Carnitine acyltransferases/génétique , Carnitine acyltransferases/métabolisme , Régulation de l'expression des gènes/physiologie , Récepteurs nicotiniques/génétique , Rat Sprague-Dawley , Transporteurs de cations organiques/génétique , Transporteurs de cations organiques/métabolisme , Transporteurs vésiculaires de l'acétylcholine/génétique , Transporteurs vésiculaires de l'acétylcholine/métabolisme , Cellules souches mésenchymateuses/métabolisme , Réaction de polymérisation en chaine en temps réel , Maxillaire/cytologie
2.
Braz. j. med. biol. res ; 46(10): 844-854, 24/set. 2013. graf
Article Dans Anglais | LILACS | ID: lil-688554

Résumé

Impaired cholinergic neurotransmission can affect memory formation and influence sleep-wake cycles (SWC). In the present study, we describe the SWC in mice with a deficient vesicular acetylcholine transporter (VAChT) system, previously characterized as presenting reduced acetylcholine release and cognitive and behavioral dysfunctions. Continuous, chronic ECoG and EMG recordings were used to evaluate the SWC pattern during light and dark phases in VAChT knockdown heterozygous (VAChT-KDHET, n=7) and wild-type (WT, n=7) mice. SWC were evaluated for sleep efficiency, total amount and mean duration of slow-wave, intermediate and paradoxical sleep, as well as the number of awakenings from sleep. After recording SWC, contextual fear-conditioning tests were used as an acetylcholine-dependent learning paradigm. The results showed that sleep efficiency in VAChT-KDHET animals was similar to that of WT mice, but that the SWC was more fragmented. Fragmentation was characterized by an increase in the number of awakenings, mainly during intermediate sleep. VAChT-KDHET animals performed poorly in the contextual fear-conditioning paradigm (mean freezing time: 34.4±3.1 and 44.5±3.3 s for WT and VAChT-KDHET animals, respectively), which was followed by a 45% reduction in the number of paradoxical sleep episodes after the training session. Taken together, the results show that reduced cholinergic transmission led to sleep fragmentation and learning impairment. We discuss the results on the basis of cholinergic plasticity and its relevance to sleep homeostasis. We suggest that VAChT-KDHET mice could be a useful model to test cholinergic drugs used to treat sleep dysfunction in neurodegenerative disorders.


Sujets)
Animaux , Mâle , Souris , Comportement animal/physiologie , Agents cholinergiques/métabolisme , Apprentissage du labyrinthe/physiologie , Phases du sommeil/physiologie , Transmission synaptique/physiologie , Vigilance/physiologie , Souris knockout , Modèles animaux
3.
Indian J Exp Biol ; 2004 Jun; 42(6): 567-9
Article Dans Anglais | IMSEAR | ID: sea-63185

Résumé

Biliary, ureteric and intestinal colic are extremely common clinical conditions associated with smooth muscle spasm. In the present study, antispasmodic activity was carried out against acetylcholine (10-640 ng/ml)-induced contractions on guinea pig ileum. Acetylcholine (10-640 ng/ml) induced concentration-dependent contraction of smooth muscle. Diclofenac, in varying concentration (9.4 x 10(-5) mol/l and 14.1 x 10(-5) mol/l) shifted the concentration response curve of acetylcholine to the right without suppressing the maximal response. However, in higher concentration diclofenac (18.9 x 10(-5) mol/l) blocked the response in an unsurmountable fashion. Further, analgin (11.09 x 10(-5), 16.63 x 10(-5) and 22.18 x 10(-5) mol/l) in equimolar concentrations did not alter the concentration response curve of acetylcholine, but in higher concentration analgin (44.36 x 10(-5) mol/l) also blocked the response in an unsurmountable fashion. Pitofenone (2.5 x 10(-6) mol/l) also, shifted the concentration response curve of acetylcholine to right in a parallel fashion with no change in maximal response. The present study confirms the potent antispasmodic activity of diclofenac-pitofenone combination in comparison to analgin-pitofenone in molar equivalent concentration (in comparison to diclofenac) against acetylcholine-induced contractions of guinea pig ileum.


Sujets)
Acétylcholine/pharmacologie , Animaux , Anti-inflammatoires non stéroïdiens/pharmacologie , Benzophénones/pharmacologie , Agents cholinergiques/métabolisme , Diclofenac/pharmacologie , Métamizole sodique/pharmacologie , Relation dose-effet des médicaments , Femelle , Cochons d'Inde , Iléum/effets des médicaments et des substances chimiques , Mâle , Contraction musculaire , Muscles lisses/effets des médicaments et des substances chimiques , Parasympatholytiques/pharmacologie , Spasme/traitement médicamenteux
4.
Indian J Exp Biol ; 2004 Apr; 42(4): 361-7
Article Dans Anglais | IMSEAR | ID: sea-59881

Résumé

Acetylcholine and cholinomimetic agents with predominant muscarinic action are known to increase the concentration of cGMP by activation of nitric oxide signaling pathway in the nociceptive conditions. The present study was aimed to investigate the NO-cGMP-PDE5 pathway in nociceptive conditions in the experimental animals. Nociceptive threshold was assessed by acetic acid-induced writhing assay (chemonociception) or carrageenan-induced hyperalgesia. Sildenafil [1-5 mg/kg, ip, 50-200 microg/paw, intraplantar (ipl)] produced dose dependent antinociception in both the tested models. Coadministration of acetylcholine (50 mcg/paw, ipl) or cholinomimetic agent, neostigmine (0.1 mcg/kg, ip and 25 ng/paw, ipl) augmented the peripheral antinociceptive effect of sildenafil. This effect was sensitive to blockade by L-NAME (20 mg/kg, ip, 100 microg/paw, ipl), a non-selective NOS inhibitor and methylene blue (1 mg/kg, ip), a guanylate cyclase inhibitor, which per se had little or no effect in both the models of nociception. Further, the per se analgesic effect of acetylcholine and neostigmine was blocked by both L-NAME and methylene blue in the models of nociception, suggesting the activation of NO-cGMP pathway. Also, both L-NAME and methylene blue blocked the per se analgesic effect of sildenafil. These results indicate the peripheral accumulation of cGMP may be responsible for antinociceptive effect, and a possible interaction between cholinergic agents and PDE5 system in models of nociception.


Sujets)
3',5'-Cyclic-GMP Phosphodiesterases/métabolisme , Acide acétique/pharmacologie , Acétylcholine/pharmacologie , Animaux , Carragénane/pharmacologie , Agents cholinergiques/métabolisme , Anticholinestérasiques/pharmacologie , GMP cyclique/métabolisme , Cyclic Nucleotide Phosphodiesterases, Type 5 , Relation dose-effet des médicaments , Association médicamenteuse , Antienzymes/pharmacologie , Femelle , Guanylate cyclase/antagonistes et inhibiteurs , Hyperalgésie/induit chimiquement , Mâle , Bleu de méthylène/pharmacologie , Souris , L-NAME/pharmacologie , Néostigmine/pharmacologie , Monoxyde d'azote/métabolisme , Nitric oxide synthase/antagonistes et inhibiteurs , Douleur/induit chimiquement , Mesure de la douleur , Inhibiteurs de la phosphodiestérase/pharmacologie , Pipérazines/usage thérapeutique , Purines , Rats , Sulfones
SÉLECTION CITATIONS
Détails de la recherche